A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradox

Psilocybin is presented as a rapid-acting, long-lasting treatment for treatment-resistant depression, with its therapeutic effects attributed to sustained structural and functional remodelling in mood-related neural circuits. The paper highlights a mechanistic paradox in the existing literature: psilocin, the active metabolite of psilocybin, can directly bind to and positively modulate TrkB receptors, yet blocking or deleting 5-HT₂A receptors abolishes psilocybin-induced dendritic spine formation, circuit rewiring, and durable antidepressant-like behaviour. The central uncertainty is how 5-HT₂A and TrkB are functionally related in producing these plastic effects.

This is a hypothesis paper rather than an empirical study. The authors state that their model is synthesised from published genetic, cellular, and behavioural data. No new participants, experiments, interventions, or statistical analyses are reported in the extracted text. The paper therefore functions as a conceptual integration of earlier findings on psilocybin, 5-HT₂A signalling, TrkB/BDNF-related plasticity, and antidepressant-like effects. The aim is to reconcile apparently conflicting evidence by proposing how receptor activation must be organised in space and time for psilocybin-related neuroplasticity to become functionally meaningful.

The authors argue that 5-HT₂A receptors are densely expressed in apical dendrites of layer V pyramidal tract neurons in the medial prefrontal cortex, which they describe as the relevant cellular substrate for psilocybin-induced plasticity. On this account, 5-HT₂A acts as a spatial gate: TrkB is widely expressed, but its activation only leads to productive synaptic remodelling in these 5-HT₂A-enriched neurons. The authors cite genetic evidence that conditional deletion of 5-HT₂A in these cells abolishes psilocybin-induced dendritic spine growth and long-term antidepressant effects, and that TrkB activation elsewhere cannot compensate. They also propose a temporal sequence. Psilocybin is said to trigger rapid 5-HT₂A-mediated calcium signalling and downstream mTOR activation, which primes the neuron and opens a transient window for plastic change. Within that window, psilocin-mediated TrkB potentiation is proposed to mature and stabilise new synapses. If 5-HT₂A signalling is absent, the window never opens and direct TrkB activation is described as insufficient to produce functional synaptic remodelling. The paper further claims that this framework helps explain why non-hallucinogenic TrkB agonists have not reproduced psilocybin’s long-term antidepressant effects in preclinical and early clinical studies, because they lack the 5-HT₂A-dependent spatial and temporal gating described here.

The authors interpret their synthesis as a resolution of the 5-HT₂A-TrkB paradox: psilocybin plasticity is not explained by a simple linear pathway, but by coordinated receptor functions in which 5-HT₂A defines the relevant cellular location and timing for plasticity, while TrkB carries out the synaptic rebuilding itself. In their view, 5-HT₂A provides the necessary permission for plasticity, and TrkB executes the structural changes. They position this account as broadly relevant to rapid-acting antidepressant pharmacology, arguing that direct engagement of plasticity-related pathways is not enough on its own unless the signal is directed to the correct neuronal substrate and aligned with a permissive molecular state. They suggest this may explain the failure of some non-hallucinogenic TrkB agonists to match psilocybin’s durable antidepressant effects. The paper is limited by its nature as a theory built from existing studies rather than new data. The authors describe the framework as testable, but the extracted text does not report formal experiments, quantitative analyses, or direct validation of the hypothesis. They imply that future work should examine whether candidate therapeutics can co-opt or mimic the 5-HT₂A-dependent gating mechanism.

The authors conclude that psilocybin’s therapeutic plasticity is best understood through a spatiotemporal gating system rather than a linear receptor cascade. In this model, 5-HT₂A determines where and when plasticity can occur, and TrkB determines the downstream synaptic changes that follow. They present the hypothesis as a testable framework for future psychedelic pharmacology and for designing next-generation rapid-acting antidepressants.